SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval
1 references·3 citing·10 second hop
Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval (2009)Incremental Advance or Seismic Shift? The…Go or No-Go? (2003)Go or No-Go?Approvals of drugs with uncertain benefit–risk profiles in Europe (2015)Approvals of drugs with uncer…Green Oncology: Cultivating Sustainability in Medical Oncology (2012)Green Oncology: Cultivating S…Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs (2011)Oncogenic Targets, Magnitude …Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma (2008)Accelerated Approval of Oncology Products: The Food and Drug Administration Experience (2011)Early market access of cancer drugs in the EU (2015)From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients (2015)Generating comparative evidence on new drugs and devices after approval (2020)Generating comparative evidence on new drugs and devices before approval (2020)How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question (2009)Meta-analysis in clinical trials (1986)Excess in the pharmaceutical industry (2004)Economics of New Oncology Drug Development (2007)
this work references cited by second hop

References

  • 2003Go or No-Go?60 cited

Cited by

  • 2015Approvals of drugs with uncertain benefit–risk profiles in Europe93 cited
  • 2011Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs68 cited
  • 2012Green Oncology: Cultivating Sustainability in Medical Oncology2 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work